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Abstract
EGFR mutations correlate with improved clinical outcome whereas KRAS mutations are associated with lack of response to
tyrosine kinase inhibitors in patients with non-small cell lung cancer (NSCLC). Endobronchial ultrasound (EBUS)-
transbronchial needle aspiration (TBNA) is being increasingly used in the management of NSCLC. Co-amplification at lower
denaturation temperature (COLD)–polymerase chain reaction (PCR) (COLD-PCR) is a sensitive assay for the detection of
genetic mutations in solid tumours. This study assessed the feasibility of using COLD-PCR to screen for EGFR and KRAS
mutations in cytology samples obtained by EBUS-TBNA in routine clinical practice. Samples obtained from NSCLC patients
undergoing EBUS-TBNA were evaluated according to our standard clinical protocols. DNA extracted from these samples was
subjected to COLD-PCR to amplify exons 18–21 of EGFR and exons two and three of KRAS followed by direct sequencing.
Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases
(94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%)
large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)). Molecular analysis of all EGFR and KRAS target
sequences was achieved in 126 of 132 (95.5%) and 130 of 132 (98.4%) of cases respectively. EGFR mutations were identified
in 13 (10.5%) of fully evaluated cases (11 in adenocarcinoma and two in NSCLC-NOS) including two novel mutations. KRAS
mutations were identified in 23 (17.5%) of fully analysed patient samples (18 adenocarcinoma and five NSCLC-NOS). We
conclude that EBUS-TBNA of lymph nodes infiltrated by NSCLC can provide sufficient tumour material for EGFR and KRAS
mutation analysis in most patients, and that COLD-PCR and sequencing is a robust screening assay for EGFR and KRAS
mutation analysis in this clinical context.
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Introduction
Epidermal growth factor receptor (EGFR) is a member of the
ErbB receptor family, a key regulator of epithelial cell proliferation
[1]. EGFR consists of an extracellular domain, a transmembrane
region and a cytoplasmic catalytic region that includes the tyrosine
kinase domain [1]. Excessive EGFR signaling upsets the balance
between cell growth and apoptosis contributing to tumourigenesis
in a wide variety of solid tumours including non-small cell lung
cancer (NSCLC) [2]. This can arise from overexpression of
EGFR, its signaling partners, or two of its ligands, EGF and TGF-
a [3,4]. Constitutive activation of EGFR tyrosine kinase activity
can be brought about by somatic mutations in the tyrosine kinase
domain of EGFR [5,6,7]. Retrospective and prospective studies in
Asian and European patients with NSCLC have shown that the
presence of EGFR mutations in exons 18–21 correlates with
superior clinical outcome to EGFR tyrosine kinase inhibitors
gefitanib and erlotinib [8,9,10]. Most NSCLC-specific EGFR
mutations are either a single amino acid substitution at codon 858
(Leucine to Argine; L858R), or deletion mutations in exon 19 that
affect the conserved LREA motif [11]. These mutations are found
in a minority of Caucasian patients with NSCLC but as many as
60% of East Asians with adenocarcinoma [8,12,13,14]. A separate
group of EGFR mutations is associated with primary as well as
acquired resistance to erlotinib and gefitinib, and these cluster in
exon 20 of the EGFR gene [15,16].
Some NSCLC also harbour mutations in Kirsten rat sarcoma
viral oncogene homolog (KRAS) encoding a GTPase downstream
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KRAS, occur in 15–30% of unselected NSCLC [20], and appear to
be mutually exclusive to EGFR mutations in NSCLC [21]. It has
been suggested that mutations in KRAS are associated with de novo
resistance to gefitinib and erlotinib [21]. Unlike EGFR mutations,
which are a positive prognostic factor, KRAS mutations in resected
NSCLC were associated with shorter overall survival than those
with EGFR mutations [17,18,19]. Taken together current evidence
suggests that EGFR and KRAS mutations define distinct subgroups
of NSCLC patients, with different responses to EGFR- targeted
therapies.
Most patients with NSCLC present at an advanced stage and
pathological diagnosis is often made from small-sized broncho-
scopic, transthoracic core biopsies or cytological samples. Most
genetic mutation analyses rely on the polymerase chain
reaction (PCR) for amplification of target sequences. Unlike
standard PCR, co-amplification at lower denaturation temper-
ature-PCR (COLD-PCR) preferentially amplifies mutant se-
quences and therefore increases the sensitivity of detecting
genetic mutations [22]. This is particularly important in
analysing the presence of genetic mutations in solid cancer
tissues, where tumour cells may be admixed with stromal and
other non-malignant tissue. Sincei tw a sf i r s td e s c r i b e d ,C O L D -
PCR has been shown to be superior to conventional PCR in a
number of applications designed to detect mutations in mixed
samples [22,23,24,25].
Endobronchial ultrasound (EBUS)-transbronchial needle
aspiration (TBNA) is a recently developed technique that
allows ultrasound-guided aspiration of mediastinal and hilar
lymph nodes and masses. Increasing data supports its use in
lung cancer diagnosis and staging as an alternative to
mediastinoscopy [26,27,28,29,30], however there are concerns
that these small cytological samples may provide insufficient
tumour material for molecular diagnosis, an area of increasing
importance in NSCLC management. This is reflected in a
recently published consensus statement on EGFR mutation
testing which recommends that tissue biopsy samples should be
used in preference to cytological samples whenever possible,
until further research establishes the reliability of mutational
data obtained from cytological samples [31]. Here we address
this question by screening for EGFR and KRAS mutations in 193
EBUS-TBNA derived cytology samples from metastatic lymph
nodes in 132 patients with NSCLC in routine clinical practice
using a single assay based on the principles of COLD-PCR and
direct sequencing.
Results
EBUS-TBNA
132 patients diagnosed with NSCLC using EBUS-TBNA
between May 2009 and February 2011 (125 Caucasian, four
Asian and three British Black) were included in this study. All
patients (n=65) with NSCLC irrespective of histological sub-type
between May 2009 and February 2010 were included in this study.
The remaining 67 patients (March 2010–February 2011) represent
consecutive patients with NSCLC, non-squamous sub-type.
Patient clinical characteristics and disease stage are shown in
Table 1. None of the patients had received treatment prior to the
procedure. Aspirates were obtained from 193 lymph nodes from
stations two to 11 (short axis diameter was 1.2+/20.5 cm) in 132
patients (Table 1). The median number of passes per lymph node
station was 4.6 (range: 1–10); this is similar to the median number
of passes per lymph node station (3.8) obtained in 972 patients
investigated at our centre by EBUS-TBNA between February
2008 and February 2011 (unpublished observations).
Morphological diagnosis and immunoprofile
Immunohistochemistry was successfully performed in 131 of
132 patients. Insufficient material was available from one patient.
Histological type was determined by a combination of morphology
(cytological slides and cellblock sections) and immunohistochem-
ical profile. In the case of adenocarcinoma, diagnosis was
supported by expression of TTF-1, CK7 or BerEP4 and negativity
for CK5 and p63. Cytomorphology and expression of CK5 and
p63 favoured squamous cell carcinoma diagnosis, while expression
of neuroendocine markers (CD56, chromogranin and synapto-
physin) and appropriate morphology established the diagnosis of
large cell neuroendocrine carcinoma. Undifferentiated NSCLC by
morphology that also lacked expression of differentiation markers
CK5, CK7, CD56, TTF-1, p63, BerEP4 resulted in the diagnosis
of NSCLC not otherwise specified (NSCLC-NOS). Based on these
criteria, 94 of the 132 patients (71.2%) were diagnosed with
adenocarcinoma, 17 (12.8%) with squamous cell carcinoma, two
with large neuroendocrine cell carcinoma (0.15%), one with large
cell carcinoma (0.07%), and 18 (13.6%) with NSCLC-NOS
(Table 1).
Mutation Analysis
The COLD-PCR and sequencing protocol was optimised to
amplify and sequence exons 18 to 21 of EGFR and codons 12, 13
and 61 of KRAS in order to detect EGFR and KRAS mutation with
sensitivity of 5–10% (mutation frequencies of 10% were detected
in all COLD-PCR runs, whereas mutation frequencies of 5% were
Table 1. Patient Characteristics.
Age
Mean 65.5 years
Range 45–81 years
Male 53 (%)
Female 47 (%)
Tumour type
Adenocarcinoma 94/132 (71.2%)
Squamous cell 17/132 (12.8%)
NSCLC-NOS
* 18/132 (13.6%)
Large cell neuroendocrine 2/132 (0.15%)
Large cell Carcinoma 1/132 (0.07%)
Lymph Node Stations sampled by EBUS-TBNA
+
2R 12/193 (6%)
2L 4/193 (2%)
4R 55/193 (29%)
4L 23/193 (12%)
7 48/193 (25%)
10R 20/193 (10%)
10L 10/193 (5%)
11R 6/193 (3%)
11L 15/193 (8%)
*Refers to not otherwise specified.
+Refers to delineation of lymph node stations by endobronchial ultrasound
(EBUS) was based on the new International Association of Study of Lung
Cancer (IASLC) lymph node map.
doi:10.1371/journal.pone.0025191.t001
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sensitivity of 30% for our standard-PCR protocol.
One of the 132 samples failed to amplify target DNA and
therefore EGFR and KRAS mutation analysis was performed in 131
of 132 samples (99.3%). The patient sample that failed DNA
amplification contained only 100 cells/section [32]. The COLD-
PCR protocol successfully amplified exons 18–21 in 126 of 131
patients (95.5%) in whom DNA was available. Amplification of
exon 21 failed in three patient samples (two adenocarcinomas and
one squamous cell carcinoma); one of these samples also failed
amplification of exon 20. Two additional patient samples failed
amplification of exon 18. Sequencing was successful for all
amplified sequences; therefore complete molecular analysis of all
four EGFR target exons was available in 126 of the 132 patients
(95.4%) and partial molecular analysis in 131 of 132 patients
included in this study (99%).
Using COLD-PCR we were able to detect EGFR mutations in
13 of 126 patients (10.3%) in whom full molecular analysis was
available (Table 2). One patient sample contained two exon 21
mutations (Table 3). Repeating the COLD-PCR and sequencing
protocol from a second cellblock independently confirmed all
mutations. Mutations were almost exclusively found in adenocar-
cinoma sub-type (11 of 13; 85%; p,0.001). One large in-frame
deletion in exon 19 and the L858R mutation were detected in two
patients with NSCLC-NOS. No EGFR mutations were detected in
17 squamous cell carcinomas between May 2009 and February
2010; mutation analysis was subsequently performed only in
patients diagnosed with NSCLC non-squamous histology. EGFR
mutations were identified in 11 of 89 (12.3%) adenocarcinomas
and 13 of 110 (12%) non-squamous histology. The L858R
mutation accounted for four of 13 (31%). We identified only one
in-frame deletion in exon 19 (D2481–2495) (Table 3). We also
identified two novel EGFR mutations; both were single amino acid
substitutions, one in exon 19 (V760M) and another in exon 20
(H805L). There was one complex mutation (L833V + L858R).
The possibility exists that novel mutations detected in this study
are artefacts; this has been linked to PCR of formalin-embedded
tissue [33,34]. Moreover, COLD-PCR as well as a standard-PCR
protocol is susceptible to polymerase-induced errors. In our study
AmpliTaq Gold was used to amplify target sequences, in contrast
to high fidelity Taq polymerase used by Li et al. [22,23,24] Using
high fidelity Taq polymerase could avoid the possibility of PCR
enrichment of PCR errors. However, it is unlikely that the novel
mutations detected in our study are due to COLD-PCR errors, as
all mutations were confirmed in separate reactions and no
mutations were detected in wild type DNA that was used as
negative control in all reactions. This would also suggest that
AmpliTaq Gold did not enrich amplicons with artificial mutations.
We also identified the less common EGFR mutations G719A,
P733S, L747P and L861Q. Another uncommon mutation
(L833V) was found together with L858R mutation. MassArray
(Sequenom Inc) and Scorpion amplified refractory mutation
system (SARMS) (DsX EGFR PCR mutation analysis kit;
QIAGEN) technologies would not have detected mutations
P733S, L747P, V760M, H805L and L833V.
KRAS mutations analysis was successful in 130 of 132 tumours
(98.4%). One sample that gave uninformative sequence also failed
EGFR mutation analysis due to paucity of tumour material. Single
amino acid substitutions involving codons 12, 13 and 61 of KRAS
were identified in 23 of 130 NSCLC (17.7%) overall (18 of 93
adenocarcinomas (19%) and five of 18 NSCLC-NOS (27.7%))
(Table 3). None were found in patients with squamous cell
tumours or in patients harbouring EGFR mutations.
Previous studies and our own validation experiments have
shown increased sensitivity of COLD-PCR compared to standard
PCR protocols [22,23,24,25,35]. Here we also performed a limited
comparison of the ability of COLD-PCR to detect EGFR and
KRAS mutations in 25 EBUS-derived adenocarcinoma cytological
aspirates with that of standard-PCR. These samples were also
analysed in parallel by COLD-PCR and SARMS (DxS EGFR
PCR kit, QIAGEN) according to manufacturer instructions. We
found standard-PCR and subsequent sequencing detected all
EGFR mutations that had been detected by COLD-PCR (L858R,
D2481–2495 and H805L). The mutation peak was more clearly
visible following COLD-PCR amplification as shown for the
L858R mutation (Figure 1A). Standard-PCR failed to detect the
KRAS G12C mutation (Figure 1B). This difference in mutation
detection between COLD-PCR and standard PCR was not
Table 2. Frequency of EGFR and KRAS mutations in
metastatic lymph nodes in NSCLC
*.
Tumour type EGFR mutations (%) KRAS mutations (%)
Adenocarcinoma 11/89 (12.3%) 18/93 (19%)
NSCLC-NOS
+ 2/18 (11.1%) 5/18 (27.7%)
Large cell neuroendocrine 0/2 0/2
Large cell carcinoma 0/1 0/1
Squamous cell 0/16 0/16
Non-squamous 13/110 (12%) 23/114 (20%)
*Refers to data for fully analysed patient samples.
+Refers to not otherwise specified.
doi:10.1371/journal.pone.0025191.t002
Table 3. EGFR and KRAS mutations detected by COLD-PCR.
EGFR Number of cases
Adenocarcinoma G719A
+ Exon 18 2
Adenocarcinoma L747P
+ Exon 19 1
NSCLC-NOS
‘ 2481-2495del15 Exon 19 1
Adenocarcinoma P733S
+ Exon 19 1
Adenocarcinoma V760M
* Exon 19 1
Adenocarcinoma H805L
* Exon 20 1
Adenocarcinoma 2319 insertion CAG2320
+ Exon 20 1
Adenocarcinoma L858R
+ Exon 21 2
Adenocarcinoma L833V
++L858R
+ Exon 21 1
Adenocarcinoma L861E
+ Exon 21 1
NSCLC-NOS
‘ L858R
+ Exon 21 1
KRAS
Adenocarcinoma G12C Exon 2 13
Adenocarcinoma G12V Exon 2 4
Adenocarcinoma G61H Exon 3 1
NSCLC-NOS
‘ G12C Exon 2 3
NSCLC-NOS
‘ G12V Exon 2 1
NSCLC-NOS
‘ G61H Exon 3 1
+Refers to known EGFR mutations.
*Refers to novel EGFR mutations.
ˆRefers to not-otherwise specified.
doi:10.1371/journal.pone.0025191.t003
Mutation Analysis in EBUS-Derived Aspirates
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25191significant (p=0.5). Using SARMS, we found no additional EGFR
mutations among these EBUS-derived adenocarcinoma aspirates.
SARMS also confirmed the L858R mutation that had been
originally identified by COLD-PCR.
Discussion
Here we report on the feasibility of using COLD-PCR to screen
for EGFR and KRAS mutations in 132 patients that had been
sampled by EBUS-TBNA according to our standard clinical
protocols. This represents the largest cohort of such patients
reported. We demonstrate complete evaluation of exons 18 to 21
in 95.5% of EGFR and exons two and three in 98.4% of KRAS
amongst EBUS-TBNA aspirates. Our results compare favourably
with three previous studies that screened EBUS-derived aspirates
for EGFR mutations. Garcia-Olive et al and Nakajima et al
successfully analysed exons 19 and 21 of EGFR in 72% (26/36)
and 93% (43/46) of patient samples respectively [36,37].
Schuurbier et al successfully analysed 77% of all samples by
standard PCR and sequencing of exons 18–21 of EGFR [38]. We
sampled broadly similar sized lymph nodes as those evaluated in
the other three studies and performed a median of 4.5 passes per
lymph node sampled; this number of passes is similar to the three-
to-four passes per node advised to establish the diagnosis of
malignancy [28,30]. Results from this and previous studies
therefore suggest that EBUS-TBNA can provide sufficient tumour
material for EGFR and KRAS mutation analysis in routine clinical
practice thus avoiding the need for more invasive surgical
sampling in these patients.
There are currently a number of methods that have been
developed to screen for EGFR mutations in NSCLC samples
where mutant DNA represents only a fraction of total purified
DNA [7]. Some assays such as SARMS and MassArray screen for
specific mutations with sensitivities of 1% and 10% respectively.
Other strategies that rely on techniques such as high resolution
melting and denaturing high performance liquid chromatography
detect most mutations without specifying the precise amino acid
substitution [7]. In some studies, microdissection of tumour DNA
from tissue samples was performed prior to DNA amplification
[39]. There is currently no general agreement on which of these
represents the best method for mutation analysis in NSCLC [31].
However, strategies based on DNA amplification and direct
sequencing are the most comprehensive as they can screen not
only for known but also novel mutations. It is recommended that
at least 30% tumour cells need to be present with more than 10%
mutant DNA for efficient mutation screening relying on standard
PCR and sequencing protocols [7].
The COLD-PCR assay used in this study detected EGFR and
KRAS mutations present in tumour DNA comprising as little as 5–
10% of total sample DNA. It is likely that, by employing a single
COLD-PCR critical denaturation temperature for some of the
amplicons tested there is a substantial enrichment (as Fig. 1 shows)
while for others there is little or no enrichment. The sensitivity so
defined of our COLD-PCR assay could have therefore been
further improved to detect mutation frequencies of less than 5%
had we developed an amplicon-specific assay using optimal
heteroduplex annealing and denaturing temperatures for each
amplicon. Sensitivity could be further enhanced by utilising more
sensitive amplicon-specific COLD-PCR assays such as that
described by Galbiati et al [40], or the Improved and Complete
Enrichment-COLD-PCR (ice-COLD-PCR) platform that can
detect mutation frequencies as low as 0.1%, [41]. It is our view
however that utilising amplicon-specific assays is unlikely to be
feasible for routine diagnostic use in the detection of multiple
mutations and may best be employed when tumour cell content is
lower than the 5–10% sensitivity threshold of our current assay.
Figure 1. Examples of comparative analysis of COLD-PCR vs standard-PCR. Sequencing electrogramme of comparative analysis of COLD-
PCR and standard-PCR amplification of EGFR exon 19 and KRAS exon 2. A: upper and lower panels are COLD and standard PCR amplification of exon
21 of EGFR from EBUS-derived aspirates from lymph nodes infiltrated by metastatic lung adenocarcinoma respectively. A shows substitution of
thymidine (T) by cytosine (C) in exon 21 of EGFR to generate L858R mutation that is evident in the COLD-PCR amplification reaction (arrow) as well as
the standard PCR reaction. The mutation peak is more clearly visible in the COLD-PCR (upper panel) compared to standard-PCR reaction (lower
panel). B upper and lower panels are COLD and standard PCR amplification of KRAS exon 2. The upper panel shows substitution of guanine (C) by
thymidine (T) to generate G12C mutation that was detected by COLD-PCR amplification (arrow). The mutation was not evident in the standard-PCR
reaction (lower panel).
doi:10.1371/journal.pone.0025191.g001
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scenario [32]. For example, we found that the median tumour cell
count in EBUS-derived lymph node aspirates was 2525 (range 65-
39800) and the median percentage tumour was 70% (range 10–
95%). This was comparable to the yield from bronchoscopic
biopsies and superior to the yield from computer tomography-
guided needle biopsies of peripheral primary lung tumours. In fact
the percentage tumour content in all sample types studied was 5%
or higher [32]. As EBUS-derived clinical samples can be
composed of less than 30% tumour cells, standard-PCR may not
be sufficiently sensitive to detect sufficiently sensitive to detect
mutations in these samples. In support of this, a limited
comparison of COLD-PCR vs standard-PCR showed that
standard-PCR failed to detect one of four mutations identified
by COLD-PCR, which also showed higher mutation peaks
(Figure 1A & 1B). Previous studies have also shown increased
sensitivity of COLD-PCR compared to standard PCR protocols
[22,23,24,25,35]. As COLD-PCR has no additional cost, we
favour its use to standard-PCR to screen for EGFR and KRAS
mutations in these clinical samples.
We found that the frequency of EGFR mutations in lung
adenocarcinomas and non-squamous NSCLC was broadly in
keeping with results from two previous large studies in European
patients with lung adenocarcinomas that found EGFR mutations in
10% and 16.6% of patients, with exon 19 deletions representing
46% and 62% of all EGFR mutations [12,14]. Two of the
mutations (V760M and H805L) detected in our patient cohort
were novel and two others (P733S, L747P) would not have been
detected by SARMS (DX Quiagen) or by MassArray (Sequenom
Inc) assays. Distinguishing novel EGFR mutations that are
clinically relevant from those that are functionally silent or
artefacts is clearly important, particularly as diverse responses to
EGFR tyrosine kinase inhibitor (TKI) therapy of patients with
NSCLC harbouring uncommon EGFR mutations were recently
reported [42]. The less common G719A and L861Q mutations
that were found in our patient cohort were shown to be sensitive to
EFFR TKI therapy and are therefore clinically significant [42].
The L747P mutation has been linked to poor responsiveness to
EGFR TKI inhibitor therapy, whilst another mutation at the same
codon (L747S) has been linked to acquired resistance to TKI
therapy. Exon 20 insertions, such as the 2319insertionGAC2320
found in our cohort, are also linked to poor response to EGFR
TKI therapy [43]. We also identified one doublet mutation
(L833V combined with L858R). Doublet mutations accounted for
6% of EGFR mutations, with approximately half of these occurring
at five codons [44]. It is interesting however that L833V in
combination with the H835L exon 21 mutation has been linked to
favourable response to gefitinib [45]. We have no information
regarding the responsiveness of our H833V+L858R mutation to
TKI therapy.
We found only one deletion in exon 19 that accounted for 7% of
all EGFR mutations. This is significantly lower (p,0.01) than the
36% frequencies of EGFR exon 19 deletions in NSCLC primary
tumour specimens analysed by COLD-PCR and direct sequencing
of exons 18–21 in our institution (unpublished). This observation
raises the possibility that exon 19 deletions may be underrepre-
sented in metastatic lymph nodes compared to primary tumours.
Park et al reported discordance between primary tumour and
lymph node metastases in NSCLC particularly for mutations in
exon 19 [46]. Moreover, Nakajima et al reported only one exon 19
deletion among 11 (9.9%) EGFR mutations in 43 EBUS-TBNA
metastatic lung adenocarcinomas in East-Asian patients [37],
whereas in primary lung adenocarcinomas exon 19 deletions
account for as much as 53% of mutations in East Asian patients
[47]. Loss of EGFR mutations in metastatic lung adenocarcinomas
compared to primary tumours has also been reported [48]. Larger
prospective studies matching analysis of primary tumour and
lymph node metastases are required to evaluate whether EGFR
exon 19 deletions, or other mutations, are underrepresented in
metastatic lymph nodes either at the time of diagnosis or in
response to treatment.
In this study we also assessed EBUS-derived needle aspirates for
KRAS mutations using COLD-PCR and found these in 19% of
lung adenocarcinomas and 27.7% of NSCLC-NOS. COLD-PCR
was previously shown to enhance KRAS mutation detection
sensitivity compared to ordinary PCR, in a variety of clinical
samples [25]. The frequency of KRAS mutations in the EBUS-
TBNA samples analysed in this study is in keeping with previous
studies that reported KRAS mutation frequency of up to 22%,
predominantly in adenocarcinomas [20] Importantly, KRAS
mutations are associated with lack of response to EGFR inhibitor
therapy in NSCLC [21]. Taken together, our results demonstrate
that by combining EGFR and KRAS mutation analysis in NSCLC
patients with non-squamous cell histology, decisions on appropri-
ateness of EGFR TKI therapy can be made in 27% of our patient
cohort.
We conclude that EBUS-TBNA of mediastinal lymph nodes
infiltrated by NSCLC can provide sufficient tumour material for
EGFR and KRAS mutation analysis in the great majority of patients
without the need to resort to more invasive surgical mediastinos-
copy or mediastinotomy. We also conclude that COLD-PCR and
sequencing protocols should be considered as a potential screening
assay for multiple EGFR and KRAS mutation analysis in this
clinical context. The ability to detect novel EGFR mutations, as we
demonstrated in this study, may also prove useful in screening for
acquired EGFR resistance mutations, an issue of emerging clinical
importance in NSCLC. Serial sampling and assessment of tumour
tissue obtained contemporaneously are increasingly recognised as
important in the clinical use of EGFR-targeted therapies. EBUS-
TBNA is a safe and minimally invasive technique that is likely to
be eminently applicable in this context.
Materials and Methods
Ethics Statement
This was an observational study performed according to our
standard clinical protocols. All patients gave their written consent
to undergo EBUS-TBNA and for the sampled material to be
analysed according to approved clinical protocols. EBUS-TBNA
was approved as a new investigational procedure by Guy’s & St
Thomas’ Hospital Clinical Governance Committee and is part of
the standard of care of patients with NSCLC. COLD-PCR is the
approved method for EGFR and KRAS mutation analysis at our
institution. EGFR and KRAS mutation analysis is part of the
standard of care of patients with NSCLC at our institution.
EBUS-TBNA
EBUS-TBNA was performed by two consultants in Respiratory
Medicine using a bronchoscope with integrated linear ultrasound
probe (Olympus 260F) and the C200 ultrasound processor in 128
patients and the alpha five-ultrasound processor in four. The
procedure was performed using conscious sedation. 22G needle
was used to aspirate each node. One air-dried and one alcohol-
fixed conventional smear was prepared from each pass by a
biomedical scientist and needle washings were rinsed in balanced
salt solution: Aqsia
TM (Bausch & Lomb, Kingston-Upon-Thames,
UK). Air-dried smears were stained with Hemacolor
TM (Merck
Chemicals Ltd, Nottingham, UK) for immediate assessment and
Mutation Analysis in EBUS-Derived Aspirates
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site evaluation (ROSE) by a consultant cytopathologist provided
real-time assessment of the aspirates and triage of cell suspensions
for cellblocks, flow cytometry or microbiology as dictated by
microscopy. Multiple aspirates from individual nodes from each
nodal station were pooled for further analysis. The same
pathologist reviewed all slides and subsequent cellblock sections,
issued a diagnosis and forwarded cellblocks to molecular pathology
laboratory for mutation analysis. Slides and all cellblocks were also
reviewed, according to our local clinical guidelines, by panel of
thoracic histopathologists and cytopathologists. Final diagnosis
and disease stage [49] was agreed after discussion at the Thoracic
Cancers multidisciplinary meeting. All consecutive patients
undergoing EBUS-TBNA between May 2009 and February
2010 and who were diagnosed with NSCLC or were staged for
their known NSCLC were included in this study. Between March
2010 and February 2011 all consecutive patients with non-
squamous NSCLC were evaluated.
Mutation Analysis
Sample processing and cell block preparation for DNA
extraction. Three 10 micron sections from these paraffin-
embedded EBUS cellblocks were deparaffinized and DNA was
isolated from the tissues using Qiagen DNA isolation kit with a
modified protocol. Briefly, deparaffinised tissues were suspended in
180 m of tissue solubilizing buffer and 70 ml of proteinase K
enzyme and incubated at 56uC overnight. After the addition of
200 ml of DNA binding buffer, the mixture was incubated at 70uC
for 10 minutes followed by 100 ml of isopropanol and
centrifugation at 16 kg for 1 minute to eliminate tissue debris.
The quality of DNA and its suitability for PCR amplification was
assessed by DNA-OK PCR kit, according to manufacturer’s
instructions.
COLD-PCR
COLD-PCR was performed according to the principles devised
by Li J et al [22] with minor modifications Multiple primers (eight-
ten per amplicon) were designed and synthesised to amplify exons
18–21 of EGFR and codons 12, 13 and 61 of KRAS. Mutated DNA
for each of the target amplicons was synthesised and serially
diluted with wild type DNA to maximal dilution of 5% (mutated to
wild type DNA). Standard and COLD-PCR reactions were then
performed using different annealing and denaturing temperatures
with each primer pair. The heteroduplex formation temperature
was required to be significantly higher than the annealing
temperature of the primers to avoid premature extension. We
evaluated different COLD-PCR parameters and selected the best
for improving sensitivity for the amplicons amplified. As some of
the primer sets produced amplification at annealing temperature
of up to 66uC, the heteroduplex annealing step was finally
performed at 71uC. Heteroduplex denaturing temperatures
between 85uC–89uC were assessed at 0.5–1uC increments before
the final heteroduplex denaturing temperature of 87uC was
selected. Final sensitivity of our COLD-PCR and sequencing
protocol was 5–10% compared to 30% for standard-PCR and
sequencing (K Tobal, unpublished data; p,0.01).
The sequences of the synthetic oligonucleotides used for the
amplification of exons 18–21 of EGFR and codons 12, 13 and 61
of KRAS are shown in Table 4. Standard and COLD-PCR
amplifications were performed in 50 ml reactions containing
2 mM MgCl2,1rmole dNTPs and 2 U of AmpliTaq Gold
(ABI). For the COLD-PCR amplification, DNA was first subjected
to a preliminary 10 cycles of normal PCR to accumulate copies of
the target sequences, followed by 40 cycles of COLD-PCR to
preferentially amplify the mutant alleles and increase the sensi-
tivity of detecting EGFR and KRAS mutations, by denaturing the
double stranded PCR amplicons followed by incubation at 71uC
for 3.5 minutes to produce mutant/wild type heteroduplexes. This
was followed by denaturing at 87uC for 20 seconds which
preferentially denatures heteroduplex amplicons thus enabling
the preferential amplification of mutant DNA. PCR parameters
were: 95uC for 10 minutes, then 10 cycles of 94uC for 30 seconds,
56uC for 30 seconds, 72uC for 30 seconds, followed by 40
cycles of 94uC 20 seconds, 71uC for 3.5 minutes, 87uC for
20 seconds, 56uC 30 seconds, 72uC 30 seconds. This is followed
by 1 cycle of 72uC for 5 minutes. PCR parameters for standard
PCR were: 95uC for 10 minutes, followed by 40 cycles of 94uC
20 seconds, 56uC 30 seconds, 72uC 30 seconds. This is followed
by 1 cycle of 72uC for 5 minutes. 5 ml of PCR products were
separated on 2% agarose gel to validate the amplification of the
various exons. Cold and standard PCR products were then
purified by Invitrogen PCR purification kit (ChargeSwitch PCR
Clean-Up Kit) and sequenced in both directions using ABI 3.7
sequencing kit. Wild type DNA was used as negative control and
mutated DNA for each amplicon was used as positive control in all
reactions.
DNA extracted from EBUS-derived aspirates from 25 of the 94-
adenocarcinoma samples was analysed in parallel by cold and
standard PCR amplification and subsequent sequencing of exons
18 to 21 of EGFR and exon 2 of KRAS. These samples were also
analysed in parallel by COLD-PCR and SARMS (DsX EGFR
PCR mutation analysis kit; QIAGEN), according to manufacturer
instructions.
Statistical Analysis
Categorical variables were analysed by x
2 or, where size was
small, by means of Fischer’s exact test. A Student’s t test was
conducted for continuous variables for comparisons between
groups.
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Table 4. PCR Oligonucleotide Sequences.
EGFR Oligonucleotide sequence
Exon18 Forward CATGGTGAGGGCTGAGGTGA
5
Exon18 Reverse CCAGAGGCCTGTGCCAGGGAC
5
Exon19 Forward CATGTGGCACCATCTCACA
5
Exon19 Reverse GACCCCCACACAGCAAAG
5
Exon 20 Forward AAGCCACACTGACGTGCCTCT
5
Exon 20 Reverse CCCGTATCTCCCTTCCCTGA
5
Exon 21 Forward CCTCACAGCAGGGTCTTCTCTG
5
Exon 21 Reverse TGGCTGACCTAAAGCCACCTC
5
KRAS
Codons 12&13 Forward TCATTATTTTTTATTATAAGGCCTGCTGAA
5
Codons 12&13 Reverse CAAAGACTGGTCCTGCACCAGTA
5
Codon 61 Forward CAATTTAAACCCACCTATAATG
5
Codon 61 Reverse CAATTTAAACCCACCTATAATG
5
doi:10.1371/journal.pone.0025191.t004
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